These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21992004)

  • 21. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
    Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
    J Med Chem; 2010 Jun; 53(11):4367-78. PubMed ID: 20462263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aurora-B kinase inhibitors for cancer chemotherapy.
    Yeung SC; Gully C; Lee MH
    Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
    Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
    Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
    Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
    Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
    Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
    McLaughlin J; Markovtsov V; Li H; Wong S; Gelman M; Zhu Y; Franci C; Lang D; Pali E; Lasaga J; Low C; Zhao F; Chang B; Gururaja TL; Xu W; Baluom M; Sweeny D; Carroll D; Sran A; Thota S; Parmer M; Romane A; Clemens G; Grossbard E; Qu K; Jenkins Y; Kinoshita T; Taylor V; Holland SJ; Argade A; Singh R; Pine P; Payan DG; Hitoshi Y
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):99-113. PubMed ID: 19609559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents.
    Wysong DR; Chakravarty A; Hoar K; Ecsedy JA
    Cell Cycle; 2009 Mar; 8(6):876-88. PubMed ID: 19221504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
    Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
    Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
    Nair JS; de Stanchina E; Schwartz GK
    Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The discovery of the potent aurora inhibitor MK-0457 (VX-680).
    Bebbington D; Binch H; Charrier JD; Everitt S; Fraysse D; Golec J; Kay D; Knegtel R; Mak C; Mazzei F; Miller A; Mortimore M; O'Donnell M; Patel S; Pierard F; Pinder J; Pollard J; Ramaya S; Robinson D; Rutherford A; Studley J; Westcott J
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3586-92. PubMed ID: 19447622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
    Anderson K; Lai Z; McDonald OB; Stuart JD; Nartey EN; Hardwicke MA; Newlander K; Dhanak D; Adams J; Patrick D; Copeland RA; Tummino PJ; Yang J
    Biochem J; 2009 May; 420(2):259-65. PubMed ID: 19284385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of 2,4-diaminopyrimidines as selective Aurora A kinase inhibitors.
    Qin WW; Sang CY; Zhang LL; Wei W; Tian HZ; Liu HX; Chen SW; Hui L
    Eur J Med Chem; 2015 May; 95():174-84. PubMed ID: 25812967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel pyrimidine-2,4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by targeting Aurora kinases.
    Salmela AL; Pouwels J; Mäki-Jouppila J; Kohonen P; Toivonen P; Kallio L; Kallio M
    Carcinogenesis; 2013 Feb; 34(2):436-45. PubMed ID: 23104179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The flavonoid eupatorin inactivates the mitotic checkpoint leading to polyploidy and apoptosis.
    Salmela AL; Pouwels J; Kukkonen-Macchi A; Waris S; Toivonen P; Jaakkola K; Mäki-Jouppila J; Kallio L; Kallio MJ
    Exp Cell Res; 2012 Mar; 318(5):578-92. PubMed ID: 22227008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.